InflaRx (NASDAQ:IFRX) Releases Earnings Results, Beats Estimates By $0.18 EPS

InflaRx (NASDAQ:IFRX - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.18, Zacks reports. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%.

InflaRx Stock Up 10.2 %

NASDAQ:IFRX traded up $0.13 on Monday, reaching $1.41. 496,668 shares of the company's stock traded hands, compared to its average volume of 215,404. InflaRx has a 12 month low of $1.13 and a 12 month high of $2.82. The stock has a 50-day simple moving average of $1.90 and a 200-day simple moving average of $1.90. The firm has a market cap of $94.66 million, a PE ratio of -1.31 and a beta of 1.98.

Analyst Ratings Changes

Separately, HC Wainwright reissued a "buy" rating and issued a $8.00 price objective on shares of InflaRx in a research note on Friday.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.